The University of Southampton
University of Southampton Institutional Repository

The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer

The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer
The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer

Resistance to adjuvant chemotherapy is a major clinical problem in the treatment of colorectal cancer (CRC). The aim of this study was to elucidate the role of an epithelial to mesenchymal transition (EMT)-inducing protein, ZEB2, in chemoresistance of CRC, and to uncover the underlying mechanism. We performed IHC for ZEB2 and association analyses with clinical outcomes on primary CRC and matched CRC liver metastases in compliance with observational biomarker study guidelines. ZEB2 expression in primary tumours was an independent prognostic marker of reduced overall survival and disease-free survival in patients who received adjuvant FOLFOX chemotherapy. ZEB2 expression was retained in 96% of liver metastases. The ZEB2-dependent EMT transcriptional programme activated nucleotide excision repair (NER) pathway largely via upregulation of the ERCC1 gene and other components in NER pathway, leading to enhanced viability of CRC cells upon oxaliplatin treatment. ERCC1-overexpressing CRC cells did not respond to oxaliplatin in vivo, as assessed using a murine orthotopic model in a randomised and blinded preclinical study. Our findings show that ZEB2 is a biomarker of tumour response to chemotherapy and risk of recurrence in CRC patients. We propose that the ZEB2-ERCC1 axis is a key determinant of chemoresistance in CRC.

DNA repair, EMT, ERCC1, ZEB2, oxaliplatin
1878-0261
2065-2083
Sreekumar, Rahul
436bd002-4ddd-4dfd-8e23-f570971a0f76
Al-Saihati, Hajir
9d4239e9-6da5-412e-8cff-7aa125c0d438
Emaduddin, Muhammad
1c4f1035-e6f8-44e9-89c5-5ccb4ef72d1b
Moutasim, Karwan
af7dd711-f6df-44f7-8c57-052bf15303af
Mellone, Massimiliano
b0301b32-14f8-4203-9026-b7f90885cab9
Patel, Ashish
da342dd9-b492-454c-b368-e7ab6ddf51d2
Kilic, Seval
6998f3e3-1277-4240-80dd-37c0efc86fc3
Cetin, Metin
d23d0fc6-999d-45aa-b66a-4af013d96038
Erdemir, Sule
d6832c7d-7868-4be3-a394-d82a67ca129b
Navio, Marta Salgado
68d30ec1-91e3-4dd9-9a9b-d333ea6a8bb8
Lopez, Maria Antonette
7cce85f1-b46b-4fd5-986a-30edc8a97872
Curtis, Nathan
de97bba8-0c86-4f07-a6c2-dbdfd96958c8
Yagci, Tamer
f2e09e8c-1299-4b37-ad56-85926d20fc56
Primrose, John N
d85f3b28-24c6-475f-955b-ec457a3f9185
Price, Brendan D.
902da737-cf7c-4064-851e-3d449f0fe1ba
Berx, Geert
03913519-35c6-4424-8dba-03240df2c955
Thomas, Gareth J.
2ff54aa9-a766-416b-91ee-cf1c5be74106
Tulchinsky, Eugene
f0b81c60-c1cd-480b-936b-56bcd383e419
Mirnezami, Alex
b3c7aee7-46a4-404c-bfe3-f72388e0bc94
Sayan, A. Emre
d1dbbcad-9c53-47c1-8b7e-1b45cc56e077
Sreekumar, Rahul
436bd002-4ddd-4dfd-8e23-f570971a0f76
Al-Saihati, Hajir
9d4239e9-6da5-412e-8cff-7aa125c0d438
Emaduddin, Muhammad
1c4f1035-e6f8-44e9-89c5-5ccb4ef72d1b
Moutasim, Karwan
af7dd711-f6df-44f7-8c57-052bf15303af
Mellone, Massimiliano
b0301b32-14f8-4203-9026-b7f90885cab9
Patel, Ashish
da342dd9-b492-454c-b368-e7ab6ddf51d2
Kilic, Seval
6998f3e3-1277-4240-80dd-37c0efc86fc3
Cetin, Metin
d23d0fc6-999d-45aa-b66a-4af013d96038
Erdemir, Sule
d6832c7d-7868-4be3-a394-d82a67ca129b
Navio, Marta Salgado
68d30ec1-91e3-4dd9-9a9b-d333ea6a8bb8
Lopez, Maria Antonette
7cce85f1-b46b-4fd5-986a-30edc8a97872
Curtis, Nathan
de97bba8-0c86-4f07-a6c2-dbdfd96958c8
Yagci, Tamer
f2e09e8c-1299-4b37-ad56-85926d20fc56
Primrose, John N
d85f3b28-24c6-475f-955b-ec457a3f9185
Price, Brendan D.
902da737-cf7c-4064-851e-3d449f0fe1ba
Berx, Geert
03913519-35c6-4424-8dba-03240df2c955
Thomas, Gareth J.
2ff54aa9-a766-416b-91ee-cf1c5be74106
Tulchinsky, Eugene
f0b81c60-c1cd-480b-936b-56bcd383e419
Mirnezami, Alex
b3c7aee7-46a4-404c-bfe3-f72388e0bc94
Sayan, A. Emre
d1dbbcad-9c53-47c1-8b7e-1b45cc56e077

Sreekumar, Rahul, Al-Saihati, Hajir, Emaduddin, Muhammad, Moutasim, Karwan, Mellone, Massimiliano, Patel, Ashish, Kilic, Seval, Cetin, Metin, Erdemir, Sule, Navio, Marta Salgado, Lopez, Maria Antonette, Curtis, Nathan, Yagci, Tamer, Primrose, John N, Price, Brendan D., Berx, Geert, Thomas, Gareth J., Tulchinsky, Eugene, Mirnezami, Alex and Sayan, A. Emre (2021) The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer. Molecular Oncology, 15 (8), 2065-2083. (doi:10.1002/1878-0261.12965).

Record type: Article

Abstract

Resistance to adjuvant chemotherapy is a major clinical problem in the treatment of colorectal cancer (CRC). The aim of this study was to elucidate the role of an epithelial to mesenchymal transition (EMT)-inducing protein, ZEB2, in chemoresistance of CRC, and to uncover the underlying mechanism. We performed IHC for ZEB2 and association analyses with clinical outcomes on primary CRC and matched CRC liver metastases in compliance with observational biomarker study guidelines. ZEB2 expression in primary tumours was an independent prognostic marker of reduced overall survival and disease-free survival in patients who received adjuvant FOLFOX chemotherapy. ZEB2 expression was retained in 96% of liver metastases. The ZEB2-dependent EMT transcriptional programme activated nucleotide excision repair (NER) pathway largely via upregulation of the ERCC1 gene and other components in NER pathway, leading to enhanced viability of CRC cells upon oxaliplatin treatment. ERCC1-overexpressing CRC cells did not respond to oxaliplatin in vivo, as assessed using a murine orthotopic model in a randomised and blinded preclinical study. Our findings show that ZEB2 is a biomarker of tumour response to chemotherapy and risk of recurrence in CRC patients. We propose that the ZEB2-ERCC1 axis is a key determinant of chemoresistance in CRC.

Text
1878-0261.12965 - Version of Record
Available under License Creative Commons Attribution.
Download (11MB)

More information

Accepted/In Press date: 12 April 2021
e-pub ahead of print date: 1 May 2021
Published date: 1 May 2021
Keywords: DNA repair, EMT, ERCC1, ZEB2, oxaliplatin

Identifiers

Local EPrints ID: 448991
URI: http://eprints.soton.ac.uk/id/eprint/448991
ISSN: 1878-0261
PURE UUID: 62cae8de-dfd5-409c-8427-54a2cbf5b616
ORCID for Massimiliano Mellone: ORCID iD orcid.org/0000-0002-4964-9340
ORCID for John N Primrose: ORCID iD orcid.org/0000-0002-2069-7605
ORCID for A. Emre Sayan: ORCID iD orcid.org/0000-0002-5291-1485

Catalogue record

Date deposited: 12 May 2021 16:49
Last modified: 17 Mar 2024 03:22

Export record

Altmetrics

Contributors

Author: Rahul Sreekumar
Author: Hajir Al-Saihati
Author: Muhammad Emaduddin
Author: Karwan Moutasim
Author: Massimiliano Mellone ORCID iD
Author: Ashish Patel
Author: Seval Kilic
Author: Metin Cetin
Author: Sule Erdemir
Author: Marta Salgado Navio
Author: Maria Antonette Lopez
Author: Nathan Curtis
Author: Tamer Yagci
Author: John N Primrose ORCID iD
Author: Brendan D. Price
Author: Geert Berx
Author: Eugene Tulchinsky
Author: Alex Mirnezami
Author: A. Emre Sayan ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×